IFIH1 and myositis disease: The clinical spectrum of anti-MDA-5 also includes CADM.3 Given that inclusion criteria in our study were focused on myositis and not on clinically amyopathic disease, that is, CADM, this may have resulted in underrepresentation of anti-MDA-5-positive patients.